An interventional study of InnoSlim® and Placebo in Hyperlipidemia, sponsored by Chung Shan Medical University. Status unknown at 1 site in Taiwan. Open to participants aged 20 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-08-14.
Sponsored by Chung Shan Medical University · Not applicable, Interventional, and Prevention
InnoSlim® has been studied for enhancing metabolic functions whereas many lab studies have demonstrated the potential efficacy of InnoSlim® for the blood sugar and blood lipids regulation. There has been no relevant human study on InnoSlim® on blood sugar and blood lipids regulation. There have reported that 2018 estimating the total costs of diagnosed diabetes have risen to $327 billion in 2017 from $245 billion in 2012. Although pharmacological methods have been developed to treat diabetes, these treatments can be costly and are not without potential adverse effects. The development of dietary agents for the prevention of diabetes could represent a cost-effective and safe means to deal with this growing public health crisis.
In this study, the investigators are investigating the effects of InnoSlim® on blood sugar and blood lipids regulation in humans. The testing sample is orally administrated to participants with pre-diabetes and hyperlipidemia humans, the efficacy parameters of blood sugar, lipid profile and other parameters, as well as adverse effects to the healthy individual, are screened during the trial, the significant difference is shown and no adverse effect reported.
821 studies on the registry are indexed under Hyperlipidemias; 105 are open to participants now.
This study's planned enrollment of 12 is below the median of 87 across 691 interventional studies indexed under Hyperlipidemias.
Browse Hyperlipidemias studies →Chung Shan Medical University is the lead sponsor of 124 studies on the registry; 26 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Subjects take 2 starch capsules before breakfast and 3 starch capsules before dinner of similar appearance per day for 6 weeks of a stage.
Dietary Supplement: InnoSlim® · Dietary Supplement: Placebo
Subjects take 2 capsules before breakfast and 3 capsules before dinner of similar appearance per day for 6 weeks of a stage.
Dietary Supplement: InnoSlim® · Dietary Supplement: Placebo
Subjects take 2 capsules before breakfast and 3 capsules before dinner of similar appearance per day for 6 weeks of a stage.
Subjects take 2 starch capsules before breakfast and 3 starch capsules before dinner of similar appearance per day for 6 weeks of a stage.
The changes of fasting blood glucose of the subjects
A randomized-double blind, and crossover trial values change of fasting blood glucose between before to after0, 3, 6, 10, 13 \& 16weeks
Time frame: 16 weeks
he changes of cholesterol of the subjects
A randomized-double blind, and crossover trial values change of blood lipid between before to after0, 3, 6, 10, 13 \& 16weeks
Time frame: 16 weeks
he changes of triglyceride of the subjects
A randomized-double blind, and crossover trial values change of blood lipid between before to after0, 3, 6, 10, 13 \& 16weeks
Time frame: 16 weeks
This study is status unknown, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chung Shan Medical University